



Namenda XR[®] (memantine) – First-time generic

- On February 21, 2018, [Amneal](#) and [Lupin](#) launched [AB-rated](#) generic versions of Allergan's [Namenda XR \(memantine\)](#) 7 mg, 14 mg, 21 mg, 28 mg extended-release capsules.
 - [Mylan](#) and [Sun](#) received FDA approval of generic Namenda XR on September 28, 2016.
 - Apotex, Anchen, and [Zydus](#) received FDA approval of generic Namenda XR on November 22, 2016, June 9, 2017, and August 3, 2017, respectively.
 - These manufacturers may launch generic Namenda XR at any time.
- Namenda XR is approved for the treatment of moderate to severe dementia of the Alzheimer's type.
- Memantine is also available generically as [tablets](#) and [oral solution](#), and as extended-release capsules in combination with donepezil ([Namzarcic[®]](#)).
 - The tablets and oral solution carry the same indication as Namenda XR.
 - Namzarcic is indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of [donepezil hydrochloride](#) once daily.
- According to IQVIA MAT data as of December 2017, Namenda XR had annual sales of approximately \$936 million in the U.S.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.